The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

EHA 2021 | Management of variant acute promyelocytic leukemia

Name: Management of variant acute promyelocytic leukemia
Uploaded: 2021-06-01T00:00:00Z
Duration: 50 s
Description: Jie Jin, MD, PhD, Zhejiang Medical University, Hangzhou, China, outlines the use of jaktinib commenting on the mechanism of action and its rationale for use in the treatment of myelofibrosis. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

Jie Jin • 1 Jun 2021

EHA 2021

Anemias Myelofibrosis Myeloproliferative Neoplasms Jaktinib

Jie Jin, MD, PhD, Zhejiang Medical University, Hangzhou, China, outlines the use of jaktinib commenting on the mechanism of action and its rationale for use in the treatment of myelofibrosis. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.